Lisa Baumbach, MD
The University of Miami's Lisa Baumbach and Maastricht University's Torik Ayoubi discuss how ethnicity-specific genetic changes may govern the risk of developing an aggressive form of breast cancer
Researchers at the University of Miami, led by Dr. Lisa Baumbach, have discovered hundreds of genetic differences between African-American, Hispanic, and Caucasian breast cancer patients that may account for an increased incidence of a particularly aggressive form of the cancer in African-American women. The discovery may pave the way for improved breast cancer treatments and prognoses based on ethnicity.
Baumbach and her team used the Almac Breast Cancer DSA research tool for their study. The Almac microarray, based on Affymetrix GeneChip® technology, includes 60,000 transcripts and is designed specifically to investigate gene expression in breast cancer. Baumbach's team identified 600 transcripts that are differentially expressed among the eight Caucasian, 10 African-American, and 10 Hispanic women in its initial sample.
A unique aspect of this study is that the team used formalin-fixed, paraffin-embedded (FFPE) tissue samples. In the past, FFPE tissues have been difficult to use because RNA extracted from these samples is usually degraded, but new technology has enabled researchers to obtain high-quality expression data from these tissues.
"Using paraffin-embedded tissue has opened up an unbelievable gold mine, not only for me, but for many other researchers in the field," said Baumbach, an associate professor at the University of Miami.
Baumbach's group found that breast tissue samples from different ethnicities include groups of differentially expressed genes. Gene expression in breast tissue from African-American women differs from that in Caucasian and Hispanic women, just as gene expression in Hispanic women differs from both African-American and Caucasian women.
In their latest study, Baumbach and her team focused on women with the "triple-negative" form of breast cancer.
More Scientist Spotlights
- Mady Hornig, MD Mady Hornig, MA, MD, Director of Translational Medicine at Columbia University, discusses the use multiplexed immunoassays for studying chronic fatigue syndrome, known as myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).
- Jizeng Jia, PhD Jizeng Jia, PhD, from the Institute of Crop Sciences, Chinese Academy of Agriculture Science, Beijing, discusses the limitations of current technologies and how they were overcome to develop the highest density wheat array commercially available.
- Gordon Mills, MD Gordon Mills, MD, PhD, of the University of Texas MD Anderson Cancer Center and "Dream Team" co-leader in Stand Up To Cancer®, discusses the importance of genomic profiling in the discovery of novel predictive markers to improve the effectiveness of cancer treatment.
- Mark I. McCarthy, MD Professor Mark McCarthy, from the University of Oxford, UK, outlines how the intersection of biobank capabilities, new study designs, and technological advances will improve our understanding of complex trait genetics.
- Bruno Stuhlmüller, PhD Bruno Stuhlmüller, PhD, head of the scientific laboratory and team leader at the Institute of the Rheumatology and Clinical Immunology department at the Charité Free University and Humboldt University, Berlin, discusses working with whole blood samples to identify mRNA and miRNA biomarkers for predictive rheumatoid arthritis treatments.
- Peter Ambros, PhD Peter Ambros, PhD, Associate Professor at the Children's Cancer Research Institute (CCRI) in Vienna, Austria discusses the way in which arrays are helping to unravel the complexities of the cancer genome and guiding patient-tailored treatment strategies.
- Austin Tanney, PhD Austin Tanney, PhD, Scientific Liaison Manager for Almac Diagnostics, UK, discusses the opportunities and challenges of working with FFPE tissue, and his visions for technologies driving towards personalized medicine.
- Jay Tiesman, PhD Procter & Gamble Company's Jay Tiesman, PhD, discusses the role of genomics in the cosmetics industry.
- Joshua Schiffman, MD The University of Utah's Joshua Schiffman, MD, discusses the use of molecular inversion probe (MIP) technology for studying copy number alterations in pediatric cancers.
- Lisa Baumbach, MD The University of Miami's Lisa Baumbach and Maastricht University's Torik Ayoubi discuss how ethnicity-specific genetic changes govern aggressive breast cancer risks.
- Chris Smith, PhD Chris Smith of Cambridge University, Tyson Clark of Affymetrix and Melissa Cline of UCSC discuss EURASNET's approach for comparing commercial microarrays.
- Robert Norgren, PhD Rob Norgren of The University of Nebraska Medical Center and Katja Nowick of Lawrence Livermore National Laboratory discuss the development of the Rhesus Macaque Genome Array.
- Yong-Jie Lu, PhD Yong-Jie Lu of Queen Mary, University of London and Colleen Elso of the Walter and Eliza Hall Institute discuss a method for rapidly identifying chromosome rearrangements.
- Genetic differences between ethnicities may determine breast cancer prognosis (pdf, 206 KB) The University of Miamiís Lisa Baumbach and Maastricht Universityís Torik Ayoubi discuss how ethnicity-specific genetic changes may govern the risk of developing an aggressive form of breast cancer.
Mitochondrial Genetic Variants Identified to Be Associated with BMI in Adults
Flaquer, A.; Baumbach, C.; Kriebel, J.; Meitinger, T.; Peters, A.; Waldenberger, M.; Grallert, H.; Strauch, K. Plos One 9(8), NPG, 2014 PubMed
AltAnalyze and DomainGraph: analyzing and visualizing exon expression data
Emig, D.; Salomonis, N.; Baumbach, J.; Lengauer, T.; Conklin, B. R.; Albrecht, M. Nucleic Acids Research 38(Supplement 2), W755-62, 2010 PubMed